ApoB vs. LDL: Which one actually predicts cardiovascular risk?
Your last cholesterol panel came back normal. Here's why that might not mean what you think it does.
You've done the right things. You get your annual bloodwork. Your doctor reviews the results, tells you your LDL is fine, and moves on. You leave feeling reassured — one less thing to worry about.
But cardiovascular disease remains the leading cause of death in both men and women. And a significant percentage of heart attacks happen in people whose LDL cholesterol was, by conventional standards, normal. Women in particular are historically underdiagnosed — more likely than men to be told their heart is fine, and more likely to pay for that reassurance later.
That gap between reassurance and reality has a name: it's called the discordance problem. And understanding it requires understanding why LDL — the number that has anchored cardiovascular medicine for decades — is an incomplete measure of risk. The more accurate signal is something called ApoB. Most physicians don't order it. Most patients have never heard of it. That needs to change.
What LDL actually measures
LDL, or low-density lipoprotein, is often called "bad cholesterol." But it's more precise to say that LDL is a particle — a protein-lipid structure that transports cholesterol through your bloodstream. When your lab reports an LDL of 110 mg/dL, what it's measuring is the concentration of cholesterol cargo carried inside those LDL particles. It tells you how much cholesterol is in the truck. It doesn't tell you how many trucks are on the road.
That distinction matters enormously.
What ApoB measures — and why it's different
Every atherogenic lipoprotein particle — LDL, VLDL, IDL, and Lp(a) — carries exactly one molecule of apolipoprotein B on its surface. One particle, one ApoB. It's a 1:1 relationship, which means an ApoB measurement gives you a direct count of the total number of atherogenic particles circulating in your blood.
This is the number that actually drives cardiovascular risk. Atherosclerosis — the buildup of plaque inside arterial walls that leads to heart attacks and strokes — begins when lipoprotein particles penetrate the endothelium (the thin, single layer of cells that lines the entire interior surface of blood vessels) and become trapped in the arterial wall. The more particles circulating, the more opportunities for that process to occur. Cholesterol concentration inside the particles is relevant, but it's secondary to particle count. What causes the damage is repeated contact — how many times the truck attempts the crossing, not how fully loaded it is.
What menopause does to cardiovascular risk
For most of their reproductive years, women carry a meaningful cardiovascular advantage over men. Estrogen supports favorable lipid profiles — larger, more buoyant LDL particles, higher HDL, lower overall atherogenic burden. It's one reason premenopausal women have substantially lower rates of cardiovascular disease than age-matched men.
The menopausal transition removes that protection, and it does so in a way that standard cholesterol testing is poorly equipped to detect.
As estrogen declines, LDL particles tend to shift in character — becoming smaller and denser. Total LDL-C may not rise dramatically. But smaller, denser particles are more atherogenic per unit of cholesterol: they penetrate the endothelium more easily, oxidize more readily, and drive plaque formation more aggressively. A woman whose LDL-C looks unchanged from her 40s to her mid-50s may have experienced a significant and unmeasured increase in atherogenic particle burden. Her ApoB tells that story. Her standard lipid panel does not.
This is why post-menopausal women, despite decades of lower cardiovascular risk, ultimately experience cardiovascular disease at rates that approach and in some populations equal men's — and why a "normal" cholesterol result in a woman in her late 40s or 50s deserves more scrutiny than it typically receives.
The discordance problem
Here's where the clinical significance becomes concrete. In many people, LDL-C and ApoB tell the same story: LDL is high, ApoB is high. But in a meaningful subset of patients — research suggests roughly 20–30% — the two values diverge. LDL looks normal or even favorable, while ApoB is elevated. This occurs most often in people with small, dense LDL particles: more particles carrying less cholesterol each. The standard cholesterol test misses this pattern entirely.
This discordance is particularly common in three groups: people with metabolic syndrome or insulin resistance, those with high triglycerides, and women in the menopausal transition — precisely because estrogen withdrawal drives the shift toward smaller, denser LDL particles described above. These patients look fine on a standard lipid panel. They leave reassured. Their arterial plaque continues to accumulate.
What the research shows
The evidence supporting ApoB as a superior cardiovascular risk predictor has been building for decades. Large-scale studies, including the AMORIS study — one of the most comprehensive analyses of cardiovascular biomarkers — found that ApoB was a stronger predictor of fatal myocardial infarction than LDL-C. The INTERHEART study, which analyzed heart attack risk across 52 countries, found the ApoB-to-ApoA1 ratio to be the single strongest lipid predictor of acute MI, outperforming the total cholesterol-to-HDL ratio that most physicians still use.
More recently, the European Atherosclerosis Society has formally recommended ApoB as the preferred marker for assessing cardiovascular risk and treatment targets — particularly in patients with high triglycerides, diabetes, obesity, or metabolic syndrome. The American Diabetes Association has followed suit. The clinical evidence for ApoB's superiority isn't emerging; it's been established for years. The gap is in clinical adoption.
The treatment gap
This isn't just a diagnostic issue — it has direct implications for how aggressively cardiovascular risk should be treated.
Statins, the most commonly prescribed cardiovascular medications, lower LDL-C reliably. But they don't always lower ApoB proportionally. Some patients achieve significant LDL-C reduction on a statin while their ApoB — and thus their atherogenic particle burden — remains elevated. Basing treatment decisions on LDL-C alone in these cases can produce a false sense of therapeutic success.
Conversely, some patients with elevated LDL-C due to large, buoyant LDL particles may have entirely normal ApoB values. Their elevated LDL-C carries relatively little atherogenic risk. Treating aggressively based on LDL-C alone in this group may represent unnecessary intervention.
The physician who orders ApoB has a more complete picture. They can treat to a more accurate target and avoid both under-treatment and over-treatment.
What your numbers should look like
For context, here are the ApoB targets that current evidence supports:
For most adults with no significant cardiovascular history, an ApoB below 90 mg/dL is considered acceptable, though many longevity physicians — including myself and others practicing within the Medicine 3.0 framework — aim for lower.
For patients with elevated cardiovascular risk, the target drops to below 80 mg/dL.
For patients with established cardiovascular disease or very high risk, current guidelines support pushing ApoB to below 60–70 mg/dL, and most longevity-focused physicians target ApoB below 60 mg/dL.
These targets are more aggressive than what most standard-of-care practice aims for. That's intentional. If the goal is to minimize lifetime atherosclerotic burden — not just to stay within "normal" reference ranges — you need numbers, and targets, that reflect that ambition.
Why this isn't standard practice yet
If ApoB is clearly superior, why isn't every physician ordering it? A few reasons. LDL testing is deeply embedded in clinical infrastructure and guidelines that have been built around it for decades. ApoB adds a modest cost to a standard lipid panel. And frankly, if a patient's LDL looks acceptable, most physicians don't go looking for additional data that might complicate the picture.
Proactive medicine asks a different question: not "is this number within the normal range?" but "is this number consistent with a trajectory toward optimal long-term health?" Those are very different standards. The first accepts the reference range as a ceiling. The second treats it as a floor.
The bottom line
LDL-C is a useful but incomplete metric. It tells part of the story. ApoB tells the rest — and in many cases, it tells a meaningfully different story. For men in midlife carrying metabolic risk they don't know about. For women navigating a menopausal transition that quietly shifts their cardiovascular profile while their standard labs stay "normal." If you've been reassured by a normal cholesterol panel without an ApoB measurement, you may be missing the most predictive cardiovascular marker in the standard toolkit.
Getting your ApoB tested is not complicated. It's a single add-on to a standard blood draw. What's more complicated is finding a physician who interprets it in the context of your full picture — your hormonal status, your metabolic health, your particle patterns — tracks it longitudinally, and is willing to intervene not when you've had an event, but before you're at risk of one.
If you haven't had your ApoB tested — or if you've had it tested but never had a physician walk you through what it means for your cardiovascular risk — that's exactly the kind of conversation we have during a longevity assessment. Schedule a free discovery call to find out what your numbers are actually telling you.
